Pulmonx to Report Second Quarter 2021 Financial Results on August 3, 2021
Pulmonx Corporation (Nasdaq: LUNG) will release its Q2 2021 financial results on August 3, 2021, after the market closes. A conference call for this announcement will follow at 1:30 p.m. PT / 4:30 p.m. ET. Investors can join by calling (833) 614-1518 domestically or (270) 823-1072 internationally, using Conference ID: 5682784. Pulmonx is a leader in minimally invasive treatments for severe lung disease, notably with its Zephyr Endobronchial Valve, used to treat over 20,000 patients globally.
- Pulmonx is a leader in minimally invasive lung disease treatments.
- Over 20,000 patients treated with Zephyr Valve, indicating strong market adoption.
- None.
REDWOOD CITY, Calif., July 20, 2021 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for lung disease, today announced that it will release financial results for the second quarter of 2021 after the close of trading on Tuesday, August 3, 2021. Company management will host a conference call to discuss financial results beginning at 1:30 p.m. PT / 4:30 p.m. ET.
Investors interested in listening to the conference call may do so by dialing (833) 614-1518 for domestic callers or (270) 823-1072 for international callers, followed by Conference ID: 5682784. A live and archived webcast of the event will be available on the “Investors” section of the Pulmonx website at https://investors.pulmonx.com/.
About Pulmonx Corporation
Pulmonx Corporation (Nasdaq: LUNG) is a global leader in minimally invasive treatments for severe lung disease. Pulmonx’s Zephyr® Endobronchial Valve, Chartis® Pulmonary Assessment System and StratX® Lung Analysis Platform are designed to assess and treat patients with severe emphysema/COPD who despite medical management are still profoundly symptomatic. Pulmonx received FDA pre-market approval to commercialize the Zephyr Valve following its designation as a “breakthrough device.” The Zephyr Valve is commercially available in more than 25 countries, with over 80,000 valves used to treat more than 20,000 patients. For more information on the Zephyr Valves, please visit www.MyLungsMyLife.com. For more information on the company, please visit www.Pulmonx.com.
Pulmonx®, Chartis®, StratX®, and Zephyr® are registered trademarks of Pulmonx Corporation.
Contact
Brian Johnston
Gilmartin Group
investors@pulmonx.com
FAQ
When will Pulmonx release its Q2 2021 financial results?
What time is the Pulmonx conference call for Q2 results?
How can I listen to the Pulmonx conference call?
What is the Zephyr Endobronchial Valve?
